ARCHIVES

Clinical Trials: Stories On Results Can Have Unintended Consequences

This article is from The Cancer Letter archive.

Vol. 24 No. 19 | May 15, 1998

Download PDF Visit The Full Archive

Related Articles

NEJM Papers, Interview With NCI’s Doroshow, Provide Justification For Regulatory Action on ESAs.

June 15, 2007

Study Finds No Link Between Tumor Grade and Relapse Risk

February 25, 2011

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

March 2, 2001

IOM Calls FDA Advisory System Sounds, Suggests Conflict Criteria Changes

March 5, 1993

Cancer Centers Form Network To Compete For Managed Care, Develop Standards

January 27, 1995

News Analysis: The Political Economy of Importation to Alleviate Cancer Drug Shortages

March 2, 2012